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case report
Hyperinsulinism/hyperammonemia 
(HI/HA) syndrome due to a 
mutation in the glutamate 
dehydrogenase gene
Síndrome de hiperinsulinemia/hiperamonemia devido a 
uma mutação no gene da glutamato desidrogenase
Maria Lúcia Corrêa-Giannella1, Daniel Soares Freire2,  
Ana Mercedes Cavaleiro1, Maria Angela Zanella Fortes1,  
Ricardo Rodrigues Giorgi1, Maria Adelaide Albergaria Pereira2
SUMMARY
The hyperinsulinism/hyperammonemia (HI/HA) syndrome is a rare autosomal dominant disea­
se manifested by hypoglycemic symptoms triggered by fasting or high­protein meals, and by 
elevated serum ammonia. HI/HA is the second most common cause of hyperinsulinemic hypo­
glycemia of infancy, and it is caused by activating mutations in GLUD1, the gene that encodes 
mitochondrial enzyme glutamate dehydrogenase (GDH). Biochemical evaluation, as well as 
direct sequencing of exons and exon­intron boundary regions of the GLUD1 gene, were per­
formed in a 6­year old female patient presenting fasting hypoglycemia and hyperammonemia. 
The patient was found to be heterozygous for one de novo missense mutation (c.1491A>G; 
p.Il497Met) previously reported in a Japanese patient. Treatment with diazoxide 100 mg/day 
promoted complete resolution of the hypoglycemic episodes. Arq Bras Endocrinol Metab. 2012;56(8):485-9
SUMÁRIO
A síndrome de hiperinsulinemia/hiperamonemia (HI/HA) é uma condição rara, de herança 
 autos sômica dominante, que se manifesta por sintomas de hipoglicemia desencadeada por je­
jum ou refeições de alto conteúdo proteico, juntamente com elevação da concentração de amô­
nia sérica. HI/HA é a segunda causa de hipoglicemia hiperinsulinêmica da infância e é causa­
da por mutações ativadoras no GLUD1, o gene que codifica a enzima mitocondrial glutamato 
desidrogenase (GDH). A avaliação bioquímica, bem como o sequenciamento direto dos éxons e 
junções éxon­íntron do gene GLUD1, foi realizada em uma paciente de 6 anos de idade com hi­
poglicemia de jejum e hiperamonemia. A paciente apresentava uma mutação de novo missense 
(c.1491A>G; p.Il497Met) em heterozigose, que havia sido previamente relatada em um paciente 
japonês. O tratamento com diazóxido 100 mg/dia promoveu resolução completa dos episódios 
hipoglicêmicos.  Arq Bras Endocrinol Metab. 2012;56(8):485-9
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INTRODUCTION
The hyperinsulinism/hyperammonemia syndrome (HI/HA) is the second most common cause 
of hyperinsulinemic hypoglycemia of infancy. It is a 
rare genetic disease caused by activating mutations in 
GLUD1, a gene located on chromosome 10q23.3., 
composed of 13 exons that encode the mitochon-
drial enzyme glutamate dehydrogenase (GDH). Most 
patients are carriers of a de novo mutation, but some 
familial cases show autosomal dominant inheritance. 
From a clinical perspective, most children manifest hy-
poglycemic symptoms after 4-6 months of age, trig-
gered by fasting or high-protein meals, together with 
elevated serum ammonia (1,2). The severity of hypo-
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+1.89]; weight, 32 kg [Z-score, +4.1]). Laboratory 
test results, including liver and renal function tests and 
concentrations of GH, IGF-I, cortisol and ACTH were 
normal (data not shown). The child presented hypo-
glycemic episodes after overnight fasting, as well as in 
the postprandial period. During an episode suggestive 
of fasting hypoglycemia, the following results were ob-
served: plasma glucose, 42 mg/dL (2.3 mM); serum 
insulin, 7.7 µU/mL; C-peptide, 3.4 ng/dL; blood 
ketone bodies (strip test), negative. Administration of 
glucagon elevated plasma glucose to 113 mg/dL (6.3 
mM).
Following demonstration of hyperinsulinemic hy-
poglycemia, an abdominal CT scan was carried out to 
exclude pancreatic neuroendocrine tumor (NET), and 
blood was collected to determine ammonia concentra-
tions. CT scan was normal and ammonia concentrations 
in two occasions were 97 and 166 μmol/L (reference 
range, 11-32 μmol/L). Both parents presented normal 
serum ammonia concentrations. With the diagnosis of 
HI/HA syndrome, the patient’s mother was instructed 
to avoid offering high protein meals and the patient 
was started on diazoxide 100 mg/day, with complete 
resolution of the hypoglycemic episodes.
Direct sequencing of the coding region of the 
GLUD1 gene revealed that the affected child was 
heterozygous for a missense mutation in exon 11 
(c.1491A>G; p.Ile497Met; based on NCBI Accession 
Number NM_005271.3). Neither parents carried this 
variant (Figure 1), suggesting a “de novo” mutation, 
which could not be definitively confirmed because a pa-
ternity test was not performed. 
Figure 1. Reverse strand sequencing electropherogram showing the substitution of T by C at nucleotide 1491 (c.1491>G), resulting in the replacement 
of isoleucine by methionine at codon 497 (p.I497M) of the GLUD1 gene in the proband. The mutation was absent in the parents. 
Proband Father Mother
Syndrome hyperinsulinism/hyperammonemia
glycemia is variable, and it is generally corrected by the 
administration of diazoxide (2).
In the present report, we describe the case of a Bra-
zilian patient with HI/HA syndrome carrying an acti-
vating mutation in the GLUD1 gene.
CASE REPORT
A 6-year-old Caucasoid girl presented generalized 
tonic-clonic seizures since the age of 7 months. Ini-
tially, she was diagnosed with epilepsy, and treatment 
with anticonvulsants was instituted, although without 
improvement in clinical status. At the age of 3 years, 
during a convulsive episode, she was hospitalized and 
biochemical hypoglycemia was documented on that 
occasion. Glucose administration prevented seizures, 
which relapsed when the child received her usual daily 
feeding routine. At the age of 6 years, she was referred 
to Hospital das Clínicas da Faculdade de Medicina da 
Universidade de São Paulo (HC-FMUSP). The child 
was delivered at term, with normal length and adequate 
weight for gestational age according to the parents (ex-
act data not available), and without perinatal complica-
tions. Initially, developmental milestones appeared to 
be normal (the patient sat with support at the age of 5 
months and walked at 14 months), but they were later 
compromised. She star ted babbling at the age of three 
years, and at admission she presented severe cognitive 
impairment. She was unable to speak complete sen-
tences. There was no family history of hypoglycemia or 
epilepsy. At admission, physical examination was nor-
mal, except for overweight (height, 123 cm [Z-score, 
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DISCUSSION
Hyperinsulinism is one of the most common causes of 
neonatal and childhood hypoglycemia (3). Insulin se-
cretion by pancreatic beta cells is triggered by increased 
intracellular calcium concentrations. On the surface 
of these cells, potassium channels composed of Kir6.2 
and SUR1 proteins control the polarization of the cell 
membrane by opening and closing its channels in re-
sponse to increased or decreased concentration of in-
tracellular adenosine triphosphate (ATP), respectively. 
When these channels are closed, the cell depolarizes, 
enabling the opening of calcium channels, increased in-
tracellular concentrations of this ion, and consequent 
release of insulin (4) (Figure 2).
causes opening of potassium channels (which is nor-
mal), and corrects hypoglycemia (Figure 2) (5).
The major regulator of insulin secretion is glucose 
which, in its metabolism, generates ATP and guano-
sine triphosphate (GTP). In addition to glucose, other 
substrates may also generate ATP and stimulate insulin 
secretion, such as fatty acids and the amino acids gluta-
mate and leucine. Glutamate is the substrate of GDH, 
an enzyme that catalyzes its oxidative deamination to 
alpha-ketoglutarate (α-KG) and ammonia. Within pan-
creatic beta cells, α-KG enters the Krebs’ cycle, leading 
to an increased generation of ATP. Leucine, which is 
present in almost all proteins ingested, is a direct stimu-
lator of GDH (Figure 3) (2,4). Under hyperglycemic 
conditions, however, the amino acids do not stimulate 
insulin release, as ATP, and mostly GTP, both gene-
rated during glucose metabolization, inhibit intracel-
lular GDH (6). Thus, GDH is allosterically activated by 
leucine and inhibited by GTP (7).
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Figure 2. Mechanisms of insulin secretion in pancreatic b-cells. α-KG, 
α-ketoglutarate; ADP, adenosine diphosphate; ATP, adenosine triphosphate; 
Ca+2, calcium ion; e-, electron; G6P, glucose 6-phosphate; GDH, glutamate 
dehydrogenase; GLUT2, glucose transporter type 2; GK, glucokinase; K+, 
potassium ion; Kir6.2, inward-rectifier potassium ion channel subunit 6.2; 
SUR1, sulfonylurea receptor 1. Adapted from Giurgea and cols. (5).
There are two basic mechanisms associated with ab-
normal increase of insulin secretion by the beta cells: 
(1) defects in potassium channels (channelopathies) 
due to inactivating mutations in ABCC8 and KCNJ11 
genes, which encode, respectively, the proteins SUR1 
and Kir6.2. These mutations lead to constitutive clo-
sure of potassium channels, so that beta cell membranes 
remain continuously depolarized, allowing constant 
insulin secretion irrespective of intracellular concen-
trations of ATP. These mutations are usually inherited 
in an autosomal recessive manner, and result in severe 
hypoglycemia during the neonatal period. In such situ-
ations, diazoxide, a drug that acts on potassium chan-
nels, is ineffective; and (2) increased generation of mi-
tochondrial ATP (metabolopathies), with consequent 
closure of potassium channels and increased insulin 
secretion. In this case, the administration of diazoxide 
Figure 3. Mechanisms of hyperinsulinism and hyperammonemia in HI/HA 
syndrome. α-KG, α-ketoglutarate; ADP, adenosine diphosphate; ATP, 
adenosine triphosphate; Ca+2, calcium ion; CPS, carbamoyl phosphate 
synthetase; GDH, glutamate dehydrogenase; GTP, guanosine triphosphate; 
K+, potassium ion; Kir6.2, inward-rectifier potassium ion channel subunit 
6.2; SUR1, sulfonylurea receptor 1. Adapted from Stanley and cols. (11).
In the presence of activating mutations in the gene 
encoding GDH, there is a reduction in the sensitivity 
of the enzyme to allosteric inhibition by GTP and ATP, 
followed by increased response of GDH to leucine, 
increased deamination of glutamate, and consequent 
rise in ATP production, which causes excessive insu-
lin secretion from beta cells in presence of glutamate 
and leucine. This sequence of events explains hyperin-
sulinemic hypoglycemia that occurs during fasting, and 
particularly in the postprandial period after protein in-
gestion (5,6,8).
The hyperactivity of GDH also results in increased 
serum concentrations of ammonia – which enable the 
Syndrome hyperinsulinism/hyperammonemia
Co
py
rig
ht
©
 A
BE
&
M
 to
do
s o
s d
ire
ito
s r
es
er
va
do
s.
488 Arq Bras Endocrinol Metab. 2012;56/8
diagnosis of the disease – and in impaired urea pro-
duction. In the liver, increased GDH activity converts 
all glutamate into ammonia and α-KG. Urea synthesis 
from ammonia is carried out by the action of carbamoyl 
phosphate synthetase (CPS), an enzyme activated by 
N-acetylglutamate (NAG), which is decreased as a re-
sult of GDH overactivity (2,9). 
HI-HA syndrome was first described in 1977 by 
Weinzimer and cols. (10) in two boys with severe hy-
perinsulinemic hypoglycemia together with hyperam-
monemia. In 1998, Stanley and cols. studied eight chil-
dren with the syndrome, identified the gene GLUD1 
and unraveled the pathophysiological mechanisms in-
volved in hyperinsulinemia and hyperammonemia (11). 
In 2002, in a multicenter series of 175 patients, hyper-
ammonaemia was found in 12 out of 69 tested patients 
with hyperinsulinemic hypoglycemia (12). Although 
the disease is rare, several case reports and some reviews 
have been published (2,9,13-18). An interesting clini-
cal aspect of HI-HA syndrome is that epilepsy is a fre-
quent finding; in a cohort of 16 patients, 15 presented 
seizures and 43% of them developed epilepsy. This is 
probably explained not only by recurrent hypoglyce-
mia, but also by chronic hyperammonaemia and by 
decreased brain concentrations of the neurotransmitter 
GABA due to increased GDH activity (15).
To date, GLUD1 mutations described were located 
in exons 6, 7, 10, 11 and 12, encoding the catalytic 
and allosteric domains of GDH (15). The mutation 
c.1491A>G; p.Ile497Met found at exon 11 of the 
Brazilian patient was also described in a Japanese pa-
tient (the mutation was previously named c.1504A>G; 
p.Ile444Met), and the functional study revealed that 
the inhibitory effects of GTP on GDH activity were 
decreased in presence of this mutation (18).
In conclusion, HI/HA syndrome is a serious condi-
tion with harmful consequences related to permanent 
brain damage that occurs when diagnosis is delayed. 
Diagnosis should be considered in all infants with hy-
perinsulinemic hypoglycemia, and should motivate the 
determination of ammonia concentrations. It is worthy 
commenting that the accuracy of ammonia measure-
ment is extremely dependent on sample collection. 
Blood samples should be collected from a stasis-free 
vein into an EDTA evacuated tube, which must be 
immediately placed on ice and delivered to the lab as 
quickly as possible; plasma should be separated from 
the sample without delay, and ammonia analysis per-
formed within 30 minutes. Some rare patients may ex-
hibit serum ammonia within the normal range. If HI/
HA is highly suspected in presence of normal serum 
ammonia, the sensitivity to leucine can be assessed by 
an oral leucine tolerance test, with administration of 
0.15 g/kg of leucine after a 4-hour fasting and deter-
mination of plasma glucose and serum insulin at times 
-30, 0, 30, 60, 90 and 120 minutes. Patients with HI/
HA syndrome develop hypoglycemia induced by leu-
cine (15). For definitive diagnosis, direct sequencing of 
the GLUD1 gene should be performed.
Disclosure: no potential conflict of interest relevant to this article 
was reported. 
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